AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30702452 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist home visit and subsequent anticoagulation expert consultation
Number of subjects: 0
Study 30702452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 31538569 — intervention group
Group type: EXPERIMENTAL
Intervention: iuMRI
Number of subjects: 570
Study 31538569 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography
Number of subjects: 570
Study 28744667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus folinic acid, 5‐fluorouracil, and irinotecan (FOLFIRI)
Number of subjects: 906
Study 28744667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 906
Study 28744667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 906
Study 27498449 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm air mattress (W)
Number of subjects: 30
Study 27498449 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 30
Study 24132248 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (up to 24 mg/day)
Number of subjects: 40
Study 24132248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22045595 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-108 40 mg daily
Number of subjects: 60
Study 22045595 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-108 80 mg daily
Number of subjects: 60
Study 22045595 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-108 120 mg daily
Number of subjects: 60
Study 19308365 — intervention group
Group type: EXPERIMENTAL
Intervention: C/P (60 mg codeine + 1000 mg paracetamol) four times daily
Number of subjects: 29
Study 19308365 — intervention group
Group type: EXPERIMENTAL
Intervention: L+C/P (levomepromazine 5 + 5 + 5 + 10 mg + C/P) four times daily
Number of subjects: 29
Study 17259517 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) therapy
Number of subjects: 608
Study 17259517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 608
Study 17259517 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 608
Study 17259517 — intervention group
Group type: EXPERIMENTAL
Intervention: TZDs in patients with diabetes
Number of subjects: 608
Study 17259517 — intervention group
Group type: EXPERIMENTAL
Intervention: TZDs in patients without diabetes
Number of subjects: 608
Study 17259517 — intervention group
Group type: COMPARATOR
Intervention: Standards of care
Number of subjects: 608
Study 15520039 — intervention group
Group type: EXPERIMENTAL
Intervention: SkinWatch programme (community-based screening for melanoma)
Number of subjects: 16383
Study 11584153 — intervention group
Group type: EXPERIMENTAL
Intervention: Biorad %CDT TIA assay
Number of subjects: 40
Study 11584153 — intervention group
Group type: COMPARATOR
Intervention: GGT levels
Number of subjects: 40
Study 9336959 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition tests instead of recall
Number of subjects: 0
Study 9336959 — intervention group
Group type: EXPERIMENTAL
Intervention: Word distractors
Number of subjects: 0
Study 9336959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonword distractors
Number of subjects: 0
Study 9336959 — intervention group
Group type: EXPERIMENTAL
Intervention: Consonant string distractors
Number of subjects: 0
Study 9336959 — intervention group
Group type: EXPERIMENTAL
Intervention: Strings of unfamiliar characters (false font)
Number of subjects: 0
Study 7515387 — intervention group
Group type: COMPARATOR
Intervention: DHEA (50 mg nightly for 6 months)
Number of subjects: 30
Study 3123249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol for 5 h
Number of subjects: 20
Study 3123249 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline for 1 h
Number of subjects: 20
Study 3123249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol for 5 h with simultaneous adrenaline during the last hour
Number of subjects: 20
Study 3123249 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 h
Number of subjects: 20
Study 29329890 — intervention group
Group type: EXPERIMENTAL
Intervention: Not-painful eccentric exercise (NPEE)
Number of subjects: 22
Study 29329890 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful eccentric exercise (PEE)
Number of subjects: 22
Study 26472406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with Ozurdex and macular laser therapy (MLT)
Number of subjects: 80
Study 26472406 — intervention group
Group type: COMPARATOR
Intervention: MLT only
Number of subjects: 80
Study 26472406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with Ozurdex and MLT
Number of subjects: 80
Study 24683657 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS
Number of subjects: 140
Study 24683657 — intervention group
Group type: COMPARATOR
Intervention: ICBG
Number of subjects: 140
Study 23516656 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated control strategy including praziquantel chemotherapy, controlling snails, building fences for bovines, safe pastures, and improving health conditions in six intervention villages.
Number of subjects: 12
Study 23516656 — intervention group
Group type: COMPARATOR
Intervention: Control group with routine interventions including praziquantel chemotherapy and controlling snails, without new interventions.
Number of subjects: 12
Study 20005750 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic coronary angiography followed by PCI if needed (Group A)
Number of subjects: 426
Study 20005750 — intervention group
Group type: COMPARATOR
Intervention: No preoperative coronary angiography (Group B)
Number of subjects: 426
Study 19033012 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril (30 mg/d)
Number of subjects: 48
Study 19033012 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg/d)
Number of subjects: 48
Study 16630941 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate 60 mg
Number of subjects: 21
Study 16630941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 12715926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue brushing (cared group)
Number of subjects: 90
Study 12715926 — intervention group
Group type: COMPARATOR
Intervention: Mouth rinsing (control group)
Number of subjects: 90
Study 10975790 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 8843
Study 8760738 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 130
Study 8760738 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 130
Study 8760738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 8760738 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Antibiotic Groups (Amoxycillin and Penicillin V)
Number of subjects: 130
Study 1313765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg orally)
Number of subjects: 0
Study 1313765 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg day-1 for three days)
Number of subjects: 0
Study 1313765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (5 mg kg-1 body weight for five days)
Number of subjects: 0
Study 1313765 — intervention group
Group type: COMPARATOR
Intervention: Control (without nifedipine)
Number of subjects: 0
Study 3860511 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% stannous fluoride (SnF2) solution using Water Pik
Number of subjects: 28
Study 3860511 — intervention group
Group type: EXPERIMENTAL
Intervention: Water irrigation (H2O) using Water Pik
Number of subjects: 28
Study 3860511 — intervention group
Group type: COMPARATOR
Intervention: Control group (no irrigation)
Number of subjects: 28
Study 3860511 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2 group after crossover
Number of subjects: 28
Study 3860511 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiologic data
Number of subjects: 28
Study 30422367 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone alone
Number of subjects: 20
Study 30422367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone in combination with Botulinum Toxin A (BTA)
Number of subjects: 20
Study 30001732 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with deqi
Number of subjects: 105
Study 30001732 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture without deqi
Number of subjects: 105
Study 30001732 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group
Number of subjects: 105
Study 30001732 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) scans
Number of subjects: 105
Study 26541264 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan
Number of subjects: 2
Study 26541264 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 2
Study 24286443 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cocoa flavanol (CF) intervention (375 mg CF, HiFI)
Number of subjects: 16
Study 24286443 — intervention group
Group type: COMPARATOR
Intervention: Low-cocoa flavanol control (9 mg CF, LoFl)
Number of subjects: 16
Study 22464260 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip device treatment
Number of subjects: 264
Study 22464260 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 264
Study 20158897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive patient education intervention (up to four weekly sessions, each lasting 30 minutes)
Number of subjects: 200
Study 20158897 — intervention group
Group type: COMPARATOR
Intervention: Normal treatment (control group)
Number of subjects: 200
Study 18084987 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior subconjunctival anaesthesia (SCA)
Number of subjects: 99
Study 18084987 — intervention group
Group type: COMPARATOR
Intervention: Inferior subconjunctival anaesthesia (SCA)
Number of subjects: 99
Study 16231532 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of gadolinium (0.2 mmol/kg)
Number of subjects: 44
Study 16231532 — intervention group
Group type: COMPARATOR
Intervention: Single dose of gadolinium (0.1 mmol/kg)
Number of subjects: 44
Study 11877267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin (group A)
Number of subjects: 1048
Study 11877267 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily low‐molecular‐weight heparin (reviparin) for 1 week (group B)
Number of subjects: 1048
Study 11877267 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily reviparin for 4 weeks (group C)
Number of subjects: 1048
Study 9787298 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lung function (FEV1)
Number of subjects: 474
Study 9787298 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lung function (FVC)
Number of subjects: 474
Study 9787298 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physical functioning
Number of subjects: 474
Study 9787298 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking habit
Number of subjects: 474
Study 9787298 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (Medical Outcomes Study SF20)
Number of subjects: 474
Study 9787298 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial aspects (social functioning, role functioning, mental health, health perceptions, pain)
Number of subjects: 474
Study 9787298 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, sex, body mass index, aneurysm diameter, graft type, hospital type, ECG characteristics, angina, previous myocardial infarction
Number of subjects: 474
Study 7542589 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine from nasal spray
Number of subjects: 15
Study 7542589 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine from nasal spray with xylometazoline
Number of subjects: 15
Study 7542589 — intervention group
Group type: COMPARATOR
Intervention: Control session measurements in disease-free state
Number of subjects: 15
Study 2675364 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiembolism stockings
Number of subjects: 70
Study 2675364 — intervention group
Group type: EXPERIMENTAL
Intervention: External pneumatic compression
Number of subjects: 70
Study 2675364 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 70
Study 401827 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) at doses of 0, 2.5, 5, 10, or 20 mg/kg/day (randomized)
Number of subjects: 75
Study 401827 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) at doses of 10 or 20 mg/kg/day (non-randomized)
Number of subjects: 75
Study 401827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 401827 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) at 5 mg/kg/day
Number of subjects: 75
Study 401827 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) (various doses)
Number of subjects: 75
Study 401827 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) (higher doses)
Number of subjects: 75
Study 31140596 — intervention group
Group type: EXPERIMENTAL
Intervention: MDZ‐NS 5 mg
Number of subjects: 262
Study 31140596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 28461862 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 for six months
Number of subjects: 25
Study 28461862 — intervention group
Group type: COMPARATOR
Intervention: Placebo for six months
Number of subjects: 25
Study 24972700 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program (12 weeks) in SLE patients (SLE-TR, n = 17)
Number of subjects: 33
Study 24972700 — intervention group
Group type: COMPARATOR
Intervention: Exercise training program (12 weeks) in healthy controls (C-TR, n = 11)
Number of subjects: 33
Study 23548119 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine use
Number of subjects: 10287
Study 23548119 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe tiredness
Number of subjects: 10287
Study 21675066 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-ventilation
Number of subjects: 38
Study 21675066 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 38
Study 19762571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus rifampin (CR)
Number of subjects: 178
Study 19762571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus doxycycline (CD)
Number of subjects: 178
Study 19762571 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline plus rifampin (DR)
Number of subjects: 178
Study 19762571 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (CR, CD, DR)
Number of subjects: 178
Study 16926256 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor letrozole
Number of subjects: 44
Study 16926256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16926256 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous puberty in KS boys
Number of subjects: 44
Study 16926256 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy boys during puberty
Number of subjects: 44
Study 15334794 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS device 'Salutaris'
Number of subjects: 19
Study 15334794 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 19
Study 10942143 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral injection of botulinum toxin (BOTOX) at a dosage of 2.5-U
Number of subjects: 19
Study 10942143 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral injection of botulinum toxin (BOTOX) at a dosage of 15-U
Number of subjects: 19
Study 10942143 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral and unilateral injections of botulinum toxin (BOTOX)
Number of subjects: 19
Study 9111463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical interventions (multidisciplinary pain clinics, exercise, cognitive-behavioral strategies, etc.)
Number of subjects: 35
Study 9111463 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical interventions
Number of subjects: 35
Study 8403290 — intervention group
Group type: EXPERIMENTAL
Intervention: Tallest height category (> or = 73 in. or 185.4 cm)
Number of subjects: 22071
Study 8403290 — intervention group
Group type: COMPARATOR
Intervention: Shortest height category (< or = 67 in. or 170.2 cm)
Number of subjects: 22071
Study 8403290 — intervention group
Group type: EXPERIMENTAL
Intervention: Height categories
Number of subjects: 22071
Study 3536529 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg once daily
Number of subjects: 23
Study 3536529 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg three times daily
Number of subjects: 23
Study 3536529 — intervention group
Group type: EXPERIMENTAL
Intervention: Postponing the third dose until 10 p.m.
Number of subjects: 23
Study 2901266 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 10 to 40 mg once daily
Number of subjects: 141
Study 2901266 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 to 160 mg twice daily
Number of subjects: 141
Study 31082951 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomated imaging analysis software used to segment and quantify plaque features, with 14 imaging variables considered for ASCVD risk score prediction.
Number of subjects: 117
Study 28365964 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation stents (group A, N=18)
Number of subjects: 43
Study 28365964 — intervention group
Group type: COMPARATOR
Intervention: Ordinary stents (group B, N=25)
Number of subjects: 43
Study 25313847 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation (PNS) of occipital nerves
Number of subjects: 157
Study 25313847 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of prior PNS implants performed (NPPIP)
Number of subjects: 157
Study 23953858 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 40
Study 23953858 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 40
Study 21715583 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 3480
Study 21715583 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP above the median
Number of subjects: 3480
Study 18061828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amphotericin B (2.5 g) and itraconazole (6 months)
Number of subjects: 6
Study 16836557 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative iron sucrose (2 x 200 mg/48 hr, IV) plus preoperative erythropoietin (EPO; 1 x 40,000 UI, sc) for patients with preoperative Hb < 130 g/L (Group A)
Number of subjects: 312
Study 16836557 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative unwashed shed blood (USB) for patients with preoperative Hb < 130 g/L (Group B)
Number of subjects: 312
Study 16836557 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 312
Study 12569270 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (17 beta‐estradiol, 100 microg/24 h)
Number of subjects: 11
Study 12569270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10863568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition newsletters with follow-up telephone interviews
Number of subjects: 480
Study 10863568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition newsletters only
Number of subjects: 480
Study 10863568 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (newsletters with and without telephone interviews)
Number of subjects: 480
Study 10863568 — intervention group
Group type: COMPARATOR
Intervention: Control group (pretest-posttest surveys only)
Number of subjects: 480
Study 9114765 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 or 100 mg once daily)
Number of subjects: 39
Study 9114765 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 or 20 mg once daily)
Number of subjects: 39
Study 9114765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 1350338 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis training (HYP)
Number of subjects: 67
Study 1350338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral coping skills training (CB)
Number of subjects: 67
Study 1350338 — intervention group
Group type: COMPARATOR
Intervention: Therapist contact control (TC)
Number of subjects: 67
Study 1350338 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 67
Study 3519549 — intervention group
Group type: EXPERIMENTAL
Intervention: Halsted mastectomy
Number of subjects: 701
Study 3519549 — intervention group
Group type: COMPARATOR
Intervention: QUART (quadrantectomy with axillary dissection and radiotherapy)
Number of subjects: 701
Study 30026341 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine
Number of subjects: 795
Study 30026341 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic
Number of subjects: 795
Study 30026341 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Number of subjects: 795
Study 30026341 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 795
Study 30026341 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus arsenic
Number of subjects: 795
Study 27423645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy
Number of subjects: 338
Study 27423645 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 338
Study 27423645 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 338
Study 27423645 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal radiotherapy (RT)
Number of subjects: 338
Study 27423645 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with stem cell rescue (HDSCR)
Number of subjects: 338
Study 27423645 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy
Number of subjects: 338
Study 27423645 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) after relapse
Number of subjects: 338
Study 27423645 — intervention group
Group type: EXPERIMENTAL
Intervention: Late relapse (>5 years from diagnosis)
Number of subjects: 338